Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
T Cells
Biotech
J&J lymphoma CAR-T hits 100% ORR in 10 patients
Of the 10 patients who had received one line of prior treatment, an objective response rate of 100% was recorded.
Darren Incorvaia
Jun 13, 2025 1:22pm
Notch begins 'significant' layoffs, blames tough environment
Jan 17, 2025 6:30am
RANKL cytokine makes the thymus more youthful in mice
Dec 5, 2024 11:45am
Ipsen taps Biomunex's MAITs to treat solid tumors in $610M bet
Dec 3, 2024 6:00am
Adaptimmune's cell therapy hits key goal in pivotal sarcoma test
Nov 13, 2024 2:57pm
Gilead bets $1.5B-plus on Merus' trispecifc T-cell engagers
Mar 6, 2024 10:02am
